Human Papillomavirus DNA Methylation as a Biomarker for Cervical Precancer: Consistency across 12 Genotypes and Potential Impact on Management of HPV-Positive Women
- 30 April 2018
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 24 (9) , 2194-2202
Abstract
Purpose: Human papillomavirus (HPV) DNA methylation testing is a promising triage option for women testing HPV positive during cervical cancer screening. However, the extent to which methylation indicates precancer for all 12 carcinogenic HPV types has not been evaluated. Experimental Design: In this nested case–control study, we tested up to 30 cases of precancer [cervical intraepithelial neoplasia grade 3 (CIN3)/adenocarcinoma in situ (AIS)] and 30 normal controls for each carcinogenic type (single infections with 16/18/31/33/35/39/45/51/52/56/58/59). Next-generation bisulfite sequencing was performed on CpG sites within the L1 and L2 genes. We calculated differences in methylation, ORs, and AUC. Using a fixed sensitivity of 80%, we evaluated the specificity and the risk of CIN3/AIS for best performing CpG sites, and compared the performance of an explorative multi-type methylation assay with current triage strategies. Results: Methylation was positively associated with CIN3/AIS across all 12 types. AUCs for the top sites ranged from 0.71 (HPV51 and HPV56) to 0.86 (HPV18). A combined 12-type methylation assay had the highest Youden index (0.46), compared with cytology (0.31) and a 5-type methylation assay, including only previously described types (0.26). The 12-type methylation assay had higher sensitivity (80% vs. 76.6%) and lower test positivity compared with cytology (38.5% vs. 48.7%). The risk of CIN3/AIS was highest for methylation positives and lowest for cytology or HPV16/18 positives. Conclusions: HPV DNA methylation is a general phenomenon marking the transition from HPV infection to precancer for all 12 carcinogenic types. Development of a combined multitype methylation assay may serve as a triage test for HPV-positive women. Clin Cancer Res; 24(9); 2194–202. ©2018 AACR.Keywords
All Related Versions
Funding Information
- NIH NCI (5U01CA078527)
This publication has 39 references indexed in Scilit:
- Elevated methylation of HPV16 DNA is associated with the development of high grade cervical intraepithelial neoplasiaInternational Journal of Cancer, 2012
- Methylation of Human Papillomavirus Type 16 Genome and Risk of Cervical Precancer in a Costa Rican PopulationJNCI: Journal of the National Cancer Institute, 2012
- Human Papillomavirus (HPV) Genotypes in Women with Cervical Precancer and Cancer at Kaiser Permanente Northern CaliforniaCancer Epidemiology, Biomarkers & Prevention, 2011
- Bismark: a flexible aligner and methylation caller for Bisulfite-Seq applicationsBioinformatics, 2011
- Quality control and preprocessing of metagenomic datasetsBioinformatics, 2011
- The Sanger FASTQ file format for sequences with quality scores, and the Solexa/Illumina FASTQ variantsNucleic Acids Research, 2009
- Multiple human papillomavirus genotype infections in cervical cancer progression in the study to understand cervical cancer early endpoints and determinantsInternational Journal of Cancer, 2009
- Ultrafast and memory-efficient alignment of short DNA sequences to the human genomeGenome Biology, 2009
- The Relationship of Community Biopsy-Diagnosed Cervical Intraepithelial Neoplasia Grade 2 to the Quality Control Pathology-Reviewed DiagnosesAmerican Journal of Clinical Pathology, 2007
- Comparisons of HPV DNA detection by MY09/11 PCR methodsJournal of Medical Virology, 2002